SCHEMBL1504418 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	DYRK1A	Q13627	1/20	0.39

▸	PRKCI	P41743	3/20	0.35

▸	AXL	P30530	2/20	0.35

▸	MKNK1	Q9BUB5	2/20	0.35

▸	MKNK2	Q9HBH9	2/20	0.35

▸	JAK2	O60674	1/20	0.34

▸	PARP1	P09874	1/20	0.33

▸	RECQL	P46063	1/20	0.33

▸	TDP1	Q9NUW8	1/20	0.33

▸	AKT2	P31751	2/20	0.33

▸	ADORA2A	P29274	1/20	0.33

▸	ADORA1	P30542	1/20	0.33

▸	HRH4	Q9H3N8	1/20	0.33

▸	KIT	P10721	1/20	0.33

▸	GSK3B	P49841	1/20	0.33

▸	JAK3	P52333	2/20	0.33

▸	TTBK1	Q5TCY1	1/20	0.33

▸	TTBK2	Q6IQ55	1/20	0.33

▸	IKBKB	O14920	1/20	0.32

▸	CHUK	O15111	1/20	0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL1504261	0.78	ALDH1A1 (0.43)	DYRK1APRKCIMKNK1MKNK2JAK2
SCHEMBL12472076	0.78	ALDH1A1 (0.43)	DYRK1APRKCIMKNK1MKNK2JAK2
SCHEMBL9918719	0.75	PRKCI (0.47)	DYRK1APRKCIAXLJAK2ADORA2A
SCHEMBL1504315	0.75	PRKCI (0.35)	DYRK1APRKCIAXLJAK2PARP1
SCHEMBL1504325	0.75	PRKCI (0.52)	DYRK1APRKCIAXLJAK2ADORA2A
SCHEMBL30678619	0.75	PRKCI (0.52)	DYRK1APRKCIAXLJAK2ADORA2A
SCHEMBL1504285	0.75	PRKCI (0.52)	DYRK1APRKCIAXLJAK2PARP1
SCHEMBL12832723	0.72	PRKCI (0.37)	PRKCIAXLMKNK1MKNK2ADORA2A
SCHEMBL17545820	0.71	PRKCI (0.36)	PRKCIAXLJAK2ADORA2AADORA1
SCHEMBL31466647	0.69	NUDT1 (0.38)	DYRK1AJAK2GSK3BJAK3TTBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20170145009-A1	HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS	EFFECTOR THERAPEUTICS, INC.	2017-05-25	—	—	US	disclosed
CN-102574863-A	Heterocyclic compounds as JANUS kinase inhibitors	BIOCRYST PHARM INC	2012-07-11	—	—	CN	disclosed
EP-2470537-A2	HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS	BIOCRYST PHARMACEUTICALS, INC. (US)	2012-07-04	—	—	EP	disclosed
US-20120149662-A1	Heterocyclic Compounds as Janus Kinase Inhibitors	BIOCRYST PHARMACEUTICALS, INC. (US)	2012-06-14	—	—	US	disclosed
US-20120149662-A1	Heterocyclic Compounds as Janus Kinase Inhibitors	BIOCRYST PHARMACEUTICALS, INC. (US)	2012-06-14	—	—	US	disclosed
US-20120149662-A1	Heterocyclic Compounds as Janus Kinase Inhibitors	BIOCRYST PHARMACEUTICALS, INC. (US)	2012-06-14	—	—	US	disclosed
WO-2011031554-A2	HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS	BIOCRYST PHARMACEUTICALS, INC. (US)	2011-03-17	—	—	WO	disclosed
WO-2011031554-A2	HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS	BIOCRYST PHARMACEUTICALS, INC. (US)	2011-03-17	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120149662-A1	Heterocyclic Compounds as Janus Kinase Inhibitors	JAK2, JAK1, JAK3	DYRK1A 2775/4885PRKCI 156/4885AXL 724/4885
US-20170145009-A1	HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS	MAP3K9, MAP3K19, MAP3K20	DYRK1A 260/4885PRKCI 376/4885AXL 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.